‘Diabetes + hyperlipidemia’ combination therapy market fueled with 3 new products

Published: 2018-05-15 22:03:26

Updated: 2018-05-15 22:03:26

The market of diabetes and hyperlipidemia has been fueled.

On the 10^th, the Ministry of Food and Drug Safety(MFDS) approved CJ HealthCare’s Atomet SR Tab 10/500mg, 10/750mg, 20/500mg and 20/750mg, Daewoong Pharmaceutical’s Lipimet SR Tab 10/500mg, 10/750mg, 20/500mg and 20/750mg, Jeil’s Limitor M Tab 10/500mg, 10/750mg, 20/500mg and 20/750mg as combination drugs for the treatment of diabetes a...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.